Review of Pharmacoeconomic Studies of Adalimumab in the Rheumatoid Arthritis Management
LIU Yue-hua1, LI Xuan2, WU Jiu-hong3*
1. School of Public Administration, Tsinghua University, Beijing 100084, China; 2. Department of Hospital Management, Tsinghua University, Shenzhen 518057, China; 3. 306 Hospital of PLA, Beijing 100101, China
Abstract��OBJECTIVE To summarize the pharmacoeconomic studies of adalimumab in the management of Rheumatoid Arthritis, discuss the cost-effectiveness and adverse reaction of combination use of adalimumab and DMARDs, and compare the economic values of TNF-�� inhibitors.METHODS Search Pubmed and MedLINE for pharmacoeconomics studies of adalimumab using in the treatment of RA. All the results are systematically summarized and assessed. RESULTS Seven studies on pharmacoeconomics assessment of adalimumab were selected and discussed. Compared with conventional DMARDs, adalimumab costs more but obviously extends the QALYs of RA patients. Adalimumab also provides significant improvement in symptom severity with less adverse reaction. The efficacy of combination use of adalimumab and MTX is better than adalimumab alone. In terms of cost and effectiveness, adalimumab has advantages over infliximab and is equal to etanercept.CONCLUSION Though adalimumab costs higher for the RA patients, it can significantly improve the quality of life when in the combination treatment with DMARDs, as well as reduce adverse reactions. Compared with other TNF-�� inhibitors, adalimumab shows superiority both in efficacy and cost. Thus, adalimumab is recommended for RA patients that don��t respond to DMARDs.
��Ծ��, ���, ��ú�. ����ľ�����������ʪ�Թؽ���ҩ�ﾭ��ѧ�о�[J]. �й�ҩѧ��־, 2017, 52(10): 886-890.
LIU Yue-hua, LI Xuan, WU Jiu-hong. Review of Pharmacoeconomic Studies of Adalimumab in the Rheumatoid Arthritis Management. Chinese Pharmaceutical Journal, 2017, 52(10): 886-890.
INTERNATIONAL ACR GROUP COMMITTEE. Treatment guide on rheumatoid arthritis[J]. Cont Med Edu, 2007, 19(3):67-73.
[2]
Rheumatic Association of Chinese Medical Association. Guide for diagnosis and treatment of reheamatoid arthritis[J]. Chin J Rheumat(�л���ʪ��ѧ��־),2010,14(4):265-270.
[3]
JENS K P, NIELS K K, ANDERS J, et al. Incidence of rheumatoid arthritis from 1995 to 2001:impact of ascertainment from multiple sources [J]. Rheumat Inter, 2009, 4:411-415.
[4]
LI Y, WANG Y, TAN S H. The research progress of rheamatoid arthritisp[J]. Chin J Orthopaed(�й����������־),2011, 19(7):581-584.
[5]
HOFF M, KVIEN T K, KALVESTEN J, et al. Adalimumab reduces handbone loss in rheumatoid arthritis independent of clinical response:subanalysis of the PREMIER study [J]. BMC Musculoskeletal Disorders, 2011, 12(1):54-59.
[6]
MITTENDORF T, DIETZ B, STERZ R, et al. Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab:an evaluation from a patient��s perspective [J]. Rheumatology, 2008,47:188-193.
[7]
VICTORIA B, MARK Q, PHILIP G C, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis [J]. Arthritis & Rheumatism, 2008, 59(10):1467-1474.
[8]
BANSBACK N J, BRENNAN A, GHATNEKAR O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden [J]. Ann Rheum Dis, 2005, 64(7):995-1002.
[9]
CHIUN-FANG CHIOU, JULIE CHOI, CAROLINA M REYES. Cost-effectiveness analysis of biological treatments for rheumatoid arthritis [J]. Expert Rev Pharm Out, 2004, 4(3):307-315.
[10]
WALSH E, MINNOCK P, SLATTERY C, et al. Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis [J]. Rheumatology, 2007,46(7):1148-1152.
[11]
W KIEVIT W, ADANG E M, FRANSEN J, et al. The effectiveness and medication costs of three anti-tumour necrosis factor �� agents in the treatment of rheumatoid arthritis from prospective clinical practice data [J]. Ann Rheum Dis, 2008,67:1229-1234.
[12]
ERIC W U, LEI C, HOWARD B, et al. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data [J]. Curr Med Res Opin, 2007, 23(8):1749-1759.
[13]
QUAN V D, CHIUN-FANG C, ROBERT W D. Review of eight pharmacoeconomic studies of the value of biologic DMARDs(adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis [J]. J Managed Care Pharm, 2006, 12(7):555-569.
[14]
BANSBACK N J, BRENNAN A, SENGUPTA N, et al. The cost effectiveness of adalimumab(HUMIRA) in UK patients with moderate to severe RA [J]. Ann Rheum Dis, 2004, 63(1):512-513.
[15]
American College of Rheumatoloy Subcommittee on Rheumaoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis:2002 update[J]. Arthritis Rheum, 2002, 46(2):328-346.
[16]
MITTENDORF T, DIETZ B, STERZ R, et al. Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis [J]. J Rheumatol, 2007, 34(12):2343-2350.
[17]
STRAND V, SINGH J A. Newer biological agents in rheumatoid arthritis:impact on health-related quality of life and productivity [J]. Drugs, 2010, 70(2):121-145.
[18]
LEDINGHAM J, DEIGHTON C. Update on the British Society for Rheumatology guidelines for prescribing TNF alpha blockers in adults with rheumatology arthritis(update of previous guidelines of April 2001)[J]. Rheumatology, 2005, 44(2):157-163.
[19]
KIMEL M, CIFALDI M, CHEN N, et al. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis(RA) on work activity for patients with early RA [J]. J Rheumatol, 2008, 35(2):206-215.
[20]
MCCABE C, CLAXTON K, CULYER A J, et al. The NICE cost-effectiveness threshold:what it is and what that means [J]. Pharmacoeconomics, 2008, 26(9):733-744.
[21]
HOFF M, KVIEN T K, KALVESTEN J, et al. Adalimumab reduces hand bone loss in the rheumatoid arthritis independent of clinical response:sub-analysis of the PREMIER study [J]. BMC Musculoskeletal Disorders, 2011, 12(1):54-59.
2017, Vol. 52 
